Skip to main content

Market Overview

BioXcel's BXCL501 Lower Dose Shows Statistical Significance On Agitation Scales

Share:

BioXcel Therapeutics Inc (NASDAQ: BTAIplans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA is scheduled in Q2 2021.

  • BXCL501 is an orally dissolving thin film formulation of dexmedetomidine (Dex).
  • In January, the company announced data from the TRANQUILITY Phase 1b/2 study in dementia-related agitation. 
  • 60 mcg dose of BXCL501 met the primary and all secondary endpoints, demonstrating statistically significant, clinically meaningful, rapid, and durable reductions in agitation with no severe or serious adverse events.
  • A lower 30 mcg dose showed numerical improvements compared to the placebo.
  • Following a routine review of TRANQUILITY study data, the company discovered that two patients were miscategorized within the 30 mcg cohort.
  • After moving the two patients into their appropriate placebo and 30 mcg groups, the data from the 30 mcg cohort were re-analyzed, resulting in the 30 mcg dose crossing over to statistical significance at the two-hour time point on agitation score.
  • Additionally, BioXcel has initiated a 46-patient study to evaluate a 40 mcg dose cohort of BXCL501. 
  • Price Action: BTAI shares are down 4.5% at $50.34 on the last check Wednesday.
 

Related Articles (BTAI)

View Comments and Join the Discussion!

Posted-In: dementia Phase 3Biotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com